Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra's Near US$1 Billion Debut Year [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
newly launched MASH therapy Rezdiffra generated close to US$1 billion in net sales in its first full year on the market. Alongside these results, Madrigal highlighted plans to expand Rezdiffra's use through the F4c trial and advance more than 10 combination and next-generation pipeline programs, aiming to build a broader MASH treatment franchise. We'll now examine how Rezdiffra's near US$1 billion first-year sales performance could shift Madrigal's investment narrative around growth and concentration risk. Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution. Madrigal Pharmaceuticals Investment Narrative Recap To own Madrigal today, you need to believe Rezdiffra can support a durable MASH franchise while the company manages heavy spending and concentration in a single drug. The latest results, with nearly US$1 billion in first-year Rezdiffra sales alongside a still-sizeable net loss, reinforce th
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success [Yahoo! Finance]Yahoo! Finance
- Madrigal: The Easiest Money May Have Been Made [Seeking Alpha]Seeking Alpha
- Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
MDGL
Earnings
- 2/19/26 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website